Cytoreductive nephrectomy in metastatic renal cancer

Current Urology Reports

Volumn 4, Issue 1, 2003, Pages 36-40

  Flanigan, Robert C ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Complete Responder; Cytoreductive Nephrectomy; Metastatic Renal Cell Cancer; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; INTERLEUKIN 2;

HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEPHRECTOMY;

EID: 0037315601     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-003-0055-6     Document Type: Article

References (27)

1. Flanigan RC: Role of surgery in patients with metastatic renal cell carcinoma. Semin Urol Oncol 1996, 14:227–229.
2. Motzer R, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408–417. DOI: 10.1016/S0022-5347(05)67889-5
3. Figlin RA, Pierce WC, Kaboo R, et al.: Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997, 158:740–745. DOI: 10.1016/S0022-5347(01)64304-0
4. Greenlee RA, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. CA Cancer J Clin 2000, 50:7–33.
5. Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon-alpha-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001, 345:1655–1659. This paper represents the largest experience to date investigating the role of cytoreductive nephrectomy in metastatic renal cancer. A 50% increase in survival was demonstrated across all prestudy variables including PS, lung-only metastases, and evaluable disease. DOI: 10.1056/NEJMoa003013
6. Mickisch GHJ, Garin A, van Poppel H, et al.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon-alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966–970. This study, which follows the exact protocol used by SWOG 8949, revealed very similar results in a smaller number of patients. The study also supported the SWOG finding of low perioperative morbidity and a small percentage of patients who were unable to proceed to IFN therapy after surgery. DOI: 10.1016/S0140-6736(01)06103-7
7. Freed S: Nephrectomy for renal cell carcinoma with metastases. Urology 1997, 9:613–616. DOI: 10.1016/0090-4295(77)90303-X
8. Spencer WF, Linehan WM, McClellan MW, et al.: Immunotherapy with interleukin-2 and interferon in patients with metastatic renal cell cancer in situ primary cancers: a pilot study. J Urol 1992, 147:24–30.
9. Figlin RA: Renal cell carcinoma: management of advanced disease. J Urol 1999, 161:381–386. DOI: 10.1016/S0022-5347(01)61897-4
10. Robertson CN, Linehan WM, Pass HI, et al.: Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 1990, 144:614–617.
11. Rackley R, Novick A, Klein E, et al.: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994, 152:1399–1403.
12. Walther MM, Alexander RB, Weiss GH: Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 1993, 42:250–257. DOI: 10.1016/0090-4295(93)90612-E
13. Fallick ML, McDermott DF, LaRock D, et al.: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997, 158:1691–1695. This review highlights the importance of patient selection in this setting and describes patients most likely to achieve a meaningful improvement in survival with IL therapy. DOI: 10.1016/S0022-5347(01)64097-7
14. Mani S, Todd MB, Katz K, et al.: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995, 154:35–40. DOI: 10.1016/S0022-5347(01)67218-5
15. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530–2540.
16. Elson PJ: Prognostic factors in metastatic renal cell carcinoma. In Current Clinical Oncology: Renal Cell Carcinoma: Molecular Biology, Immunology and Clinical Management. Edited by Bukowski RM, Novick AC. Totowa, NJ: Humanan Press; 2000.
17. Muss H, Constanzi JJ, Leavitt R, et al.: Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987, 5:286–291.
18. Umeda T, Niijima T: Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 1986, 58:1231–1235. DOI: 10.1002/1097-0142(19860915)58:6<1231::AID-CNCR2820580610>3.0.CO;2-#
19. Fisher RI, Coltman CA Jr, Doroshaw JH, et al.: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 1988, 108:518–523.
20. Walther MM, Yang JC, Pass HI, et al.: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997, 158:1675–1678. DOI: 10.1016/S0022-5347(01)64091-6
21. Walther MM, Lyne JC, Libutti SK, Linehan WM: Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 1999, 53:496–501. DOI: 10.1016/S0090-4295(98)00562-7
22. Pantuck AJ, Zisman A, Chao D, et al.: Survival advantage of interleukin-2 over interferon immunotherapy when combined with cytoreductive nephrectomy based on SWOG 8949-matched populations. J Urol 2002, 167:166.
23. Slaton JW, Perrotte P, Balbay MD, et al.: Reassessment of the selection criteria for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 2000, 163(Suppl 4):179.
24. Wood CG, Huber N, Madsen L, et al.: Clinical variables that predict survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol 2001, 165(Suppl 5):184.
25. Wolf JS, Aronson FR, Small EJ, Carroll PR: Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol 1994, 55:7–13. DOI: 10.1002/jso.2930550104
26. Bennett RT, Lerner SE, Taub HC, et al.: Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995, 154:32–34. DOI: 10.1016/S0022-5347(01)67217-3
27. Levy DA, Swanson DA, Slaton JW, et al.: Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol 1998, 159:1168–1173. DOI: 10.1016/S0022-5347(01)63542-0